Unlearn
CA - San FranciscoBiotechnology
Focus: Unlearn develops machine-learning technology that creates digital twins of patients in clinical trials, positioned as a B2B software/services provider to the biopharma industry rather than a traditional drug developer. The company operates at the intersection of AI/ML and clinical trial optimization, serving as an enabling technology platform.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Open Jobs
4-2 this month
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Should You Work at Unlearn?
AI assessmentUnlearn is a high-risk, high-optionality early-stage AI/ML platform play best suited for technologists seeking upside in clinical trial innovation with tolerance for uncertainty.
Why Work Here
- Early-stage AI/ML platform in high-growth clinical trial tech space with potential for meaningful impact on drug development efficiency
- Concentrated hiring in Technology (3 roles) signals investment in core engineering capability and product development
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Unlearn
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.